Ocular Biometry OCR: a machine learning algorithm leveraging optical character recognition to extract intra ocular lens biometry measurements.

Given close relationships between ocular structure and ophthalmic disease, ocular biometry measurements (including axial length, lens thickness, anterior chamber depth, and keratometry values) may be leveraged as features in the prediction of eye diseases. However, ocular biometry measurements are often stored as PDFs rather than as structured data in electronic health records. Thus, time-consuming and laborious manual data entry is required for using biometry data as a disease predictor.

Virtual Human Retina: Simulating Neural Signalling, Degeneration, and Responses to Electrical Stimulation.

Introduction: Current brain-based visual prostheses pose significant challenges impeding adoption such as the necessarily complex surgeries and occurrence of more substantial side effects due to the sensitivity of the brain. This has led to much effort toward vision restoration being focused on the more approachable part of the brain - the retina. Here we introduce a novel, parameterized simulation platform that enables study of human retinal degeneration and optimization of stimulation strategies.

Noncanonical PI(4,5)P2 coordinates lysosome positioning through cholesterol trafficking.

In p53-deficient cancers, targeting cholesterol metabolism has emerged as a promising therapeutic approach, given that p53 loss dysregulates sterol regulatory element-binding protein 2 (SREBP-2) pathways, thereby enhancing cholesterol biosynthesis. While cholesterol synthesis inhibitors such as statins have shown initial success, their efficacy is often compromised by the development of acquired resistance. Consequently, new strategies are being explored to disrupt cholesterol homeostasis more comprehensively by inhibiting its synthesis and intracellular transport.

Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.

Background And Objective: Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) used in the upfront and refractory settings for metastatic renal cell carcinoma (mRCC). However, there are limited data on the efficacy of subsequent TKI therapies after lenvatinib. We investigated the activity of TKI therapies after lenvatinib in patients with mRCC.